S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The Bio-Tech Stock That Needs Your Attention! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The Bio-Tech Stock That Needs Your Attention! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
The Bio-Tech Stock That Needs Your Attention! (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The Bio-Tech Stock That Needs Your Attention! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The Bio-Tech Stock That Needs Your Attention! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
The Bio-Tech Stock That Needs Your Attention! (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The Bio-Tech Stock That Needs Your Attention! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The Bio-Tech Stock That Needs Your Attention! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
The Bio-Tech Stock That Needs Your Attention! (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The Bio-Tech Stock That Needs Your Attention! (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The Bio-Tech Stock That Needs Your Attention! (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
The Bio-Tech Stock That Needs Your Attention! (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Forecast, Price & News

$38.45
-0.02 (-0.05%)
(As of 09/27/2023 ET)
Compare
Today's Range
$38.23
$39.26
50-Day Range
$37.50
$44.03
52-Week Range
$29.85
$59.46
Volume
847,869 shs
Average Volume
1.26 million shs
Market Capitalization
$5.07 billion
P/E Ratio
22.49
Dividend Yield
N/A
Price Target
$54.27

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
41.2% Upside
$54.27 Price Target
Short Interest
Bearish
5.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
1.09mentions of Halozyme Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$4.23 M Sold Last Quarter
Proj. Earnings Growth
44.35%
From $2.48 to $3.58 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.01 out of 5 stars

Medical Sector

31st out of 976 stocks

Biological Products, Except Diagnostic Industry

3rd out of 157 stocks


HALO stock logo

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Price History

HALO Stock News Headlines

The Bio-Tech Stock That Needs Your Attention!
There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
H.C. Wainwright Sticks to Their Buy Rating for Halozyme (HALO)
Expert Ratings for Halozyme Therapeutics
Goldman Sachs Sticks to Its Hold Rating for Halozyme (HALO)
Halozyme Therapeutics Q2 2023 Earnings Preview
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
393
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$54.27
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+41.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$202.13 million
Pretax Margin
37.47%

Debt

Sales & Book Value

Annual Sales
$773.65 million
Cash Flow
$2.56 per share
Book Value
$1.26 per share

Miscellaneous

Free Float
128,887,000
Market Cap
$5.07 billion
Optionable
Optionable
Beta
1.24

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 60)
    M.R.C.P., Pres, CEO & Director
    Comp: $1.45M
  • Ms. Nicole  LaBrosseMs. Nicole LaBrosse (Age 40)
    Sr. VP & CFO
    Comp: $727.04k
  • Dr. Michael J. LaBarre Ph.D. (Age 59)
    Sr. VP & Chief Technical Officer
    Comp: $723.24k
  • Mr. Mark Snyder Esq.
    Chief Legal Officer
  • Ms. Tram Bui
    Head of Investor Relations & Corp. Communications
  • Ms. Amy Marinne Fox
    Chief HR Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Dr. Christopher Bryant Ph.D. (Age 62)
    Chief Manufacturing Officer & Head of Technical Operations
  • Ms. Kristin Schwartzbauer
    Head of Quality
  • Mr. Gary Grote
    Chief Commercial Officer













HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price forecast for 2023?

11 analysts have issued 12-month price targets for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $68.00. On average, they predict the company's stock price to reach $54.27 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2023?

Halozyme Therapeutics' stock was trading at $56.90 on January 1st, 2023. Since then, HALO stock has decreased by 32.4% and is now trading at $38.45.
View the best growth stocks for 2023 here
.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our HALO earnings forecast
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.09. The biopharmaceutical company had revenue of $221.04 million for the quarter, compared to analysts' expectations of $201.91 million. Halozyme Therapeutics had a net margin of 30.21% and a trailing twelve-month return on equity of 254.75%.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $2.65-$2.75 for the period, compared to the consensus EPS estimate of $2.61. The company issued revenue guidance of $825.00 million-$845.00 million, compared to the consensus revenue estimate of $823.06 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (5.66%), Snyder Capital Management L P (3.28%), Geode Capital Management LLC (2.07%), Marshall Wace LLP (1.76%), Thrivent Financial for Lutherans (1.58%) and Northern Trust Corp (1.53%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends
.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $38.45.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.07 billion and generates $773.65 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.71 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

The company employs 393 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -